Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

310 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study.
Holdaas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Grönhagen-Riska C, Neumayer HH, Maes B, Ambühl P, Hartmann A, Staffler B, Jardine AG; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Holdaas H, et al. Among authors: olsson ag. Am J Transplant. 2005 Dec;5(12):2929-36. doi: 10.1111/j.1600-6143.2005.01105.x. Am J Transplant. 2005. PMID: 16303007 Clinical Trial.
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Pedersen TR, et al. Among authors: olsson ag. Am J Cardiol. 2004 Sep 15;94(6):720-4. doi: 10.1016/j.amjcard.2004.06.003. Am J Cardiol. 2004. PMID: 15374773 Clinical Trial.
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).
Holme I, Strandberg TE, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Holme I, et al. Among authors: olsson ag. Atherosclerosis. 2009 Aug;205(2):522-7. doi: 10.1016/j.atherosclerosis.2009.01.023. Epub 2009 Jan 24. Atherosclerosis. 2009. PMID: 19327776 Clinical Trial.
Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial.
Fellström B, Holdaas H, Jardine AG, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Staffler B, Pedersen TR; Assessment of Lescol in Renal Transplantation Study Investigators. Fellström B, et al. Among authors: olsson ag. Transplantation. 2005 Jan 27;79(2):205-12. doi: 10.1097/01.tp.0000147338.34323.12. Transplantation. 2005. PMID: 15665769 Clinical Trial.
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial.
Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Logan JO, Pedersen TR; Assessment of Lescol in Renal Transplantation Study Investigators. Fellström B, et al. Among authors: olsson ag. Kidney Int. 2004 Oct;66(4):1549-55. doi: 10.1111/j.1523-1755.2004.00919.x. Kidney Int. 2004. PMID: 15458450 Clinical Trial.
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Holdaas H, et al. Among authors: olsson ag. Lancet. 2003 Jun 14;361(9374):2024-31. doi: 10.1016/S0140-6736(03)13638-0. Lancet. 2003. PMID: 12814712 Clinical Trial.
fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study.
Jardine AG, Holdaas H, Fellström B, Cole E, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambühl P, Olsson AG, Holme I, Fauchald P, Gimpelwicz C, Pedersen TR; ALERT Study Investigators. Jardine AG, et al. Among authors: olsson ag. Am J Transplant. 2004 Jun;4(6):988-95. doi: 10.1111/j.1600-6143.2004.00445.x. Am J Transplant. 2004. PMID: 15147434 Clinical Trial.
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).
Pedersen TR, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Lindahl C, Szarek M. Pedersen TR, et al. Among authors: olsson ag. Am J Cardiol. 2010 Aug 1;106(3):354-9. doi: 10.1016/j.amjcard.2010.03.033. Am J Cardiol. 2010. PMID: 20643245 Clinical Trial.
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Holme I, Szarek M, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Holme I, et al. Among authors: olsson ag. Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):315-20. doi: 10.1097/HJR.0b013e32832130f5. Eur J Cardiovasc Prev Rehabil. 2009. PMID: 19322096 Clinical Trial.
310 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page